Contradictory and weak evidence on the effectiveness of anti-emetics for MTX-intolerance in JIA-patients

Pediatr Rheumatol Online J. 2018 Feb 15;16(1):13. doi: 10.1186/s12969-018-0229-x.

Casper G Schoemaker^{1

2

3

4}, E H Pieter van Dijkhuizen⁵, Sebastiaan J Vastert^{5

6}

¹ Department of Pediatric Rheumatology and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Room KC.03.063.0, P.O. box 85090, 3508 AB, Utrecht, Netherlands. C.G.Schoemaker-3@umcutrecht.nl.
² Netherlands JIA Patient and Parent Organization, Member of ENCA, Rijen, The Netherlands. C.G.Schoemaker-3@umcutrecht.nl.
³ National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands. C.G.Schoemaker-3@umcutrecht.nl.
⁴ Faculty of Medicine, Utrecht University, Utrecht, Netherlands. C.G.Schoemaker-3@umcutrecht.nl.
⁵ Department of Pediatric Rheumatology and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Room KC.03.063.0, P.O. box 85090, 3508 AB, Utrecht, Netherlands.
⁶ Faculty of Medicine, Utrecht University, Utrecht, Netherlands.

No abstract available

Keywords: Anti-emetics; Co-medication; Juvenile Idiopathic Arthritis (JIA); MTX-intolerance; Methotrexate.

Publication types